Fierce’s Drug Safety Summit (formerly known as REMS Summit) serves to educate the drug safety community on current challenges, opportunities, and improvements in managing risk evaluation & mitigation strategies and pharmacovigilance. This event will allow large, mid-sized pharma, and biotech leaders to come together to share insights on ensuring patient safety, adhering to global safety regulations, AI and machine learning integration, collaborating with vendors, and safety risk management, among other topics.
Evidera is proud to sponsor a Panel Discussion titled Take your REMS program further to maximize its value on Tuesday, 8 March 2022, at 11:15 a.m. EST moderated by Debbie Cheslow, Senior Director, Risk Management Programs, PPD, part of Thermo Fisher Scientific. Panelists include Kal Elhoregy, Director, Risk Evaluation and Mitigation Strategy (REMS), Amneal; Tina Latch, Senior Director, Medical Affairs | Risk Management, Endo Pharmaceuticals; and Jason Ancell, Director, Pharmacovigilance & Epi | REMS Development, Implementation, Gilead Sciences.